The agenda for the 11 June 2014 Transparency Commission meeting is now available.  The Commission will examine the following health care technologies:

• Multicomponent meningococcal Group B vaccine (Bexsero) - new vaccine
• Nabiximols (Sativex) - new medicine
• Lapatinib ditosylate monohydrate (Tyverb) - new indication
• Propranolol hydrochloride (Hemangiol) - new indication
• Cladribine (Leustatin) - Re-evaluation of ASMR
• Pentostatin (Nipent) - Re-evaluation of ASMR
• Hemin (human) (Normosang) - Re-evaluation of ASMR

The Commission will also conduct appeal hearings for the following health care technologies:

• Anakinra (Kineret)

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2014-06/odj_ct_11062014_internet.pdf